NIPER Hajipur and Boehringer Ingelheim India have partnered to accelerate translational pharmaceutical research, aiming to bridge the gap between lab discoveries and real world therapies.
Glimpse:
NIPER Hajipur and Boehringer Ingelheim India have signed a five year MoU to strengthen translational pharma research. The collaboration will provide researchers access to the opnMe® platform, enabling faster drug discovery, skill development, and innovation in India’s pharmaceutical ecosystem.
In a significant step toward strengthening India’s pharmaceutical innovation ecosystem, NIPER Hajipur has entered into a strategic partnership with Boehringer Ingelheim India to advance translational research and accelerate drug development.
The collaboration is formalized through a five year Memorandum of Understanding (MoU) aimed at promoting joint research, academic exchange, and capacity building in pharmaceutical sciences. The agreement was signed in New Delhi in the presence of senior government officials, underscoring its national importance.
A key highlight of the partnership is access to Boehringer Ingelheim’s opnMe® open science platform, which provides researchers with compounds, data, and tools to support early stage drug discovery. This is expected to significantly enhance scientific collaboration and enable researchers to generate proof of concept data that can be scaled into preclinical development.
The initiative also focuses on building research capacity at NIPER Hajipur by offering hands on training opportunities for students and strengthening expertise in translational pharmacology. By integrating academic research with industry resources, the partnership aims to bridge the gap between laboratory discoveries and real world therapeutic applications.
Experts highlight that such industry academia collaborations are critical for driving innovation in India’s pharma sector, enabling faster commercialization of research and development of next generation therapies. The partnership aligns with broader national goals to build an innovation driven healthcare ecosystem and strengthen India’s position in global drug discovery.
Overall, the collaboration positions NIPER Hajipur as a key center for translational pharmacology and reinforces the growing role of open science in accelerating healthcare innovation.
“Bridging science and real world medicine, this partnership aims to turn research into life saving therapies faster than ever.”
By
HB Team
Related News
